Archive for Uncategorized

Heart Failure 2013 LA Showcase of SoCal Heart Disease Startups Breakthrough First of Kind Technologies Will Be Presented

Heart Failure 2013 LA Showcase

17th Annual Meeting Information

Now Open:

Maintenance of Certification
ABIM-approved Self-Evaluation of Medical Knowledge Module on Advanced Heart Failure and Transplant Cardiology worth 10 points towards Maintenance of Certification (MOC).

Heart Failure 2013 LA Showcase of SoCal Heart Disease Startups Breakthrough First of Kind Technologies Will Be Presented


LA Heart Failure 2013Heart Failure 2013 LA will be held at the Millennium Biltmore Hotel all day on Saturday April 6th. Leonhardt Ventures and the Cal-X Stars Life Science Business Accelerator are co-sponsoring @ 5:30pm a side showcase of startups that address heart and cardiovascular disease, most of them based in Southern California or with strong SoCal ties.

Companies to be showcased include:
  • MyoStim Pacers – World’s first heart failure pacemaker with ability to recruit repairative stem cells to damaged and weakened heart tissue.
  • Bioheart, Inc. – Phase III leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type known to grow new contractile muscle in the depths of scar tissue.
  • BioPace – World’s first biological pacemaker made entirely of living cells.
  • CoroStim – World’s first vibrational energy emitting pacemaker that prevents plaque formation in high risk coronary arteries.
  • BioLeonhardt – Combination electrical stimulation and multi-stage cell and gene therapy method, composition and devices for treating advanced heart failure. Featuring combined utilization of MicroRNAs, nutrient time release SDF-1, hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells. First method under testing with up to 36 repeat injection sessions of stem cells over time via a needle catheter.
  • Cardiobridge – Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented.
  • AortaCell – Method and device to treat aortic aneurysms non-invasively with an abdominal belt that delivers focal wireless electrical energy to weakened aortic wall that causes repairative autologous stem cells to home to that chosen treatment location.
  • EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter and endothelial progenitor cells.
  • MyoValve – Cell seeding method and device for heart valve leaflets invivo or invitro. Designed to reduce risk of calcification and valve replacement.
  • Valvublator – Percutaneous catheter device for de-calcifying heart valves so a patient may keep their own valve instead of getting an artificial implant.
  • HeartScore – Composite scoring system of genetic, blood and scan test results (some point of care) that are loaded into the SecondBeat wearable wrist watch for a baseline score. The watch has an infrared sensor that measures real time endothelial health. The baseline score goes up or down if the patient eats well, exercises well and is compliance with all doctor prescribed medicines and protocols. The composite HeartScore is clearly viewable to patients to help real time guidance of their heart and cardiovascular health.
About Leonhardt Ventures
Since 1983 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions. In the 1980’s the group developed market leadership in patented polyurethane balloon catheters including drug, stem cell and radiation delivery systems. In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft). The team completed the first ever truly percutaneous repair of an aortic aneurysm without surgery in Melbourne, Australia in 1995. Published the first thoracic aortic dissection repair with stent grafts paper in The New England Journal of Medicine in 1999. The first conformance sealing stent graft. The first above renal fixation stent graft. The first customized to fit individual patient stent grafts. The first multi-stage low profile stent graft. The first removable stent graft. The first foam and bioglue sealing cuff for stent grafts. The first use of muscle stem cells to reinforce aortic wall necks after stent graft placement. The team developed and patented the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters. Leonhardt patented inventions include the first heart pacemaker able to recruit repairative stem cells to damaged heart tissue (MyoStim Pacers). In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with Bioheart MyoCell. That led to the first Phase III double blinded, randomized, placebo controlled trial for stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart MyoCell pts 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline). The team is preparing to complete the first ever biological pacemaker implantation in a human patient within the next 12 months (BioPace).
About Cal-X Stars
Cal-X Stars is a 5 year program business accelerator based in Santa Monica, California. Cal-X Stars also operates Cal-Xelerator a 12 week business startup launch accelerator. Both Cal-X Stars and Cal-Xelerator specialize in life science companies with a stem cell focus and social good enterprises with positive cash flow. Both accelerators guide firms through the California Qualification By Permit financings up to $5 million via Cal-X Crowdfund.
About Heart Failure 2013 LA
Heart Failure 2013 LA has been designed to continue a tradition of providing a comprehensive, high level and clinically oriented update on prevention, diagnosis and management of heart failure. The program is structured to include lectures presented by experts in the field combined with interactive panel discussions. In addition the program will provide an update on cutting edge therapies including the use of gene therapy, neuroregulin and stem cell therapy in patients with heart failure.

Howard Leonhardt
Leonhardt Ventures
1531 6th Street, Unit 401
Santa Monica, California, 90401

Telephone: (310) 310-2534

Note: Leonhardt Vineyards Gold Medal winning California wines will be served free of charge to attendees.

Copyright © 2013 Heart Failure Society of America, All rights reserved.


Posted in: Uncategorized

Leave a Comment (0) →

How Crowdfunding’s Secondary Market May Evolve

Wall Street

One of the interesting points that emerged from last week’s Sunshine Act meeting of the SEC Advisory Committee on Small and Emerging Companies was the following recommendation:

The U.S. Securities and Exchange Commission should facilitate and encourage the creation of a separate U.S. equity market or markets for small and emerging companies, in which investor participation would be limited to sophisticated investors, and small and emerging companies would be subject to a regulatory regime strict enough to protect such investors but flexible enough to accommodate innovation and growth by such companies.

In referencing “sophisticated investors,” the SEC is specifically referencing accredited investors. The SEC cannot make an exchange, but this recommendation suggests a willingness to help solve a big problem for small business. Small business equity is illiquid, and this fact hinders economic growth.

One of the largest risks to investing in startups and small businesses is the inherent lack of liquidity. Although we advocate for an exchange which is open to everyone, any new secondary market which provides an additional avenue for investor liquidity is a significant net positive. More liquidity means more capital for private companies which means more job producing startups and small businesses.

Ryan Feit, CEO – SeedInvest

See all four recommendations from the SEC’s recent Sunshine Act meeting

During the meeting, the possibility of unlimited participation in an exchange such as this was discussed. Whether or not a new exchange for small companies is created and no matter who is allowed to participate, a vision for what happens to investment crowdfunding shares after the initial offering is becoming more clear.

There are now three paths the secondary market can take:

  1. Investment crowdfunding portals list their own shares
    This is the approach Symbid is taking, where investors that purchase shares of companies listed on the Symbid platform can also sell those shares on the same platform. Crowdfunding portals would then act as primary and secondary markets.
  2. Shares are listed on a private securities marketplace
    Think SecondMarket, who recently announced a partnership with CircleUp. The crowdfunding portal is the primary market and a private marketplace acts as a secondary market in a strategic partnership.
  3. Shares are listed on a stock exchange
    Small businesses would list their shares on an exchange with less regulatory overhead (and less cost) as compared to a NYSE or NASDAQ.


Reaction to the recommendation has been pointed, with many criticizing the accredited limitation as just one more way the cards are set to be stacked against our proverbial Main Street investors. Daryl H. Bryant, CEO of equity crowdfunding platform StartupValley, thinks this type of exchange has a limited upside. “Implementing an exclusive exchange like this will not foster entrepreneurship or job growth in this country and will just continue to increase the number of investment opportunities for accredited investors,” he said.

Vincent Molinari, CEO of GATE Technologies, thinks the recommendation may just be the first step in a larger process. “What I think they’re messaging here is we have to get this right and we’re not so sure how to do that, so let’s start with a level of investors who… preconceived, right or wrong… may be able to take more risk given their net worth profile.”

“Start there, let it iterate, get it right, and then perhaps open it to the individual investor which effectively really gets to the point of democratization of capital formation,” he said.

On thing seems certain: the SEC is taking the first steps toward facilitating and encouraging a new stock exchange for small business. If created, it could help alleviate the liquidity problems facing small companies in the United States today. Partnered with crowdfunding, this could transform how entrepreneurs raise capital and how investors participate in their journey.

Featured image courtesy Manu_H on Flickr | NYSE Image courtesy digitizedchaos on Flickr


Posted in: Uncategorized

Leave a Comment (0) →